It ultimately limits the success of therapies such as monoclonal antibody-bases therapies, EGFR- and EGFRvIII-specific small molecule inhibitors, or vaccines, because it is not possible to address all single glioma cells with only one specific treatment. This evidence concerns the gene EGFR and glioma.